A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Gout

In brief

This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial respectively (SEL-212/301 and SEL-212/302). Analysis of primary and key efficacy were performed at Day 28 of Treatment Period 6. Safety was monitored throughout the study.

Key facts

Study ID

NCT04596540

Run by

Swedish Orphan Biovitrum

People needed

153

Starts

2020-11-30

Expected to finish

2023-01-12

Last updated by the study team

2025-12-03

Who can join

Age: 19 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has negative results of an FDA Emergency Use Authorized COVID-19 molecular assay for detection of SARS-CoV-2 RNA from a nasal or oropharyngeal specimen;
• History of symptomatic gout defined as:
• ≥ 3 gout flares within 18 months of Screening or
• Presence of ≥ 1 gout tophus or
• Current diagnosis of gouty arthritis
• At the Screening Visit: male age 21 - 80 years, inclusive, or female of non-childbearing potential age 21-80 years, inclusive, where nonchildbearing potential is defined as:
• > 6 weeks after hysterectomy with or without surgical bilateral salpingo-oophorectomy or
• Post-menopausal (> 24 months of natural amenorrhea or in the absence of >24 months of amenorrhea, one documented confirmatory FSH measurement)
• Has chronic refractory gout defined as having failed to normalize sUA and whose signs and symptoms are inadequately controlled with any of the xanthine oxidase inhibitors, or for whom these drugs are contraindicated for the patient;
• Has at the Screening Visit SUA ≥ 7 mg/dL
• Negative serology for HIV-1/-2 and negative antigen to hepatitis B and negative antibodies to hepatitis C;

You may not qualify if…

• Has a history of anaphylaxis, severe allergic reactions, or severe atopy;
• Has a history of any allergy to pegylated products, including, but not limited to pegloticase (Krystexxa®), peginterferon alfa-2a (Pegasys®), peginterferon alfa-2b (PegIntron®), pegfilgrastim (Neulasta®), pegaptanib (Macugen®), pegaspargase (Oncaspar®), pegademase (Adagen®), peg-epoetin beta (Mircera®), pegvisomant (Somavert®) certolizumab pegol (Cimzia®), naloxegol (Movantik®), peginesatide (Omontys®), and doxorubicin liposome (Doxil®);
• Is taking and cannot discontinue known major CYP3A4/P-gp inhibitors or major CYP3A4/P-gp inducers at least 14 days before dosing. Patients must remain off these medications for the duration of the study, including natural products such as St. John's Wort or grapefruit juice.
• Is taking drugs known to interact with rapamycin (sirolimus - Rapamune®) such as cyclosporine, diltiazem, erythromycin, ketoconazole, posaconazole, voriconazole, itraconazole, rifampin, verapamil unless they are stopped 14 days prior to dosing and will not be used/prescribed during the trial.
• Had major surgery within 3 months of initial screening.
• Had a gout flare during Screening that was resolved for less than 1 week prior to first treatment with study drug (exclusive of chronic synovitis/arthritis) unless the patient has a history of inter-flare intervals of < 1 week.
• Has uncontrolled diabetes at Screening with HbA1c ≥ 8.5%;
• Has fasting Screening glucose > 240 mg/dL;
• Has fasting Screening triglyceride > 500 mg/dL;
• Has fasting Screening low-density lipoprotein (LDL) > 200 mg/dL;
• Has glucose-6-phosphate dehydrogenase (G6PD) deficiency;
• Has uncontrolled hypertension defined as blood pressure > 170/100 mmHg at Screening and 1 week prior to dosing
• Individual laboratory values which are exclusionary
• White blood cell count (WBC) < 3.0 x109/L
• Serum aspartate aminotransferase (AST) or alanine amino transferase (ALT) > 3x upper limit of normal (ULN) in the absence of known active liver disease
• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2
• Urine albumin creatinine ratio (UACR) > 30 mg/g
• Hemoglobin (Hgb) < 9 g/dL
• Serum phosphate < 2.0 mg/dL
• Is receiving ongoing treatment for arrhythmia, including placement of an implantable defibrillator, unless considered stable and on active treatment;
• Has evidence of unstable cardiovascular disease or unstable cerebrovascular vascular disease. This includes patients who have had a cardiac/vascular event(s) in the last 3 months including heart attack, stroke or vascular bypass surgery or patients who are deemed, by their physician or PI, to have active cardiovascular, cerebrovascular or peripheral vascular symptoms/disease inadequately controlled by medication;
• Has congestive heart failure, New York Heart Association Class III or IV;
• Unless clinically stable and/or appropriately treated, electrocardiogram (ECG) with evidence of clinically significant arrhythmia or other abnormalities that, in the opinion of the investigator, are consistent with significant underlying cardiac disease;
• History of significant hematological disorders within 5 years or autoimmune disorders, and/or patient is currently immunosuppressed or immunocompromised;
• Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek, Fasturtec), pegloticase (Krystexxa®®), pegadricase (SEL 037))

Where it is running

• Omegas Research Consultants LLC — DeBary, Florida, United States
• Sweet Hope Research Specialty, Inc — Hialeah, Florida, United States
• Homestead Associates in Research,Inc — Miami, Florida, United States
• D&H National Research Centers — Miami, Florida, United States
• Panax Clinical Research — Miami Lakes, Florida, United States
• Napa Research — Pompano Beach, Florida, United States
• Clinical Research of West Florida, Inc. — Tampa, Florida, United States
• Conquest Research — Winter Park, Florida, United States
• Horizon Clinical Research — Fayetteville, Georgia, United States
• Arthritis Center of North Georgia, LLC — Gainesville, Georgia, United States
• Injury Care Medical Center — Boise, Idaho, United States
• Great Lakes Clinical Trials at Ravenswood Rheumatology — Chicago, Illinois, United States
• Great Lakes Clinical Trials LLC — Chicago, Illinois, United States
• The Center for Rheumatology and Bone Research — Wheaton, Maryland, United States
• University Of Michigan — Ann Arbor, Michigan, United States
• Elite Clinical Research, LLC — Jackson, Mississippi, United States
• Rutgers- New Jersey Medical School — Newark, New Jersey, United States
• Medication Management of Greensboro — Greensboro, North Carolina, United States
• Triad Clinical Trials — Greensboro, North Carolina, United States
• Carolina Research Center, Inc — Shelby, North Carolina, United States
• META Medical Research Institute LLC — Dayton, Ohio, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
• New Phase Research and Development — Knoxville, Tennessee, United States
• Amarillo Center for Clinical Research, Ltd. — Amarillo, Texas, United States
• Clinical Research Of West Florida Incorporated — Clearwater, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.